Xiaozhen Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xiaozhen Wang has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Ze Li
Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, China
4 shared publications - Rong Wang
Central Laboratory, Xuanwu Hospital, Capital Medical University, Beijing, China
3 shared publications - Aiping Wen
Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, China
2 shared publications - Dandan Li
Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, China
2 shared publications Xu Zhang
Central Laboratory, Xuanwu Hospital, Capital Medical University, Beijing, China
2 shared publicationsCaizhen Lv
Central Laboratory, Xuanwu Hospital, Capital Medical University, Beijing Geriatric Medical Research Center, Key Laboratory for Neurodegenerative Disease of Ministry of Education, Beijing, PR China
1 shared publication
Latest Publications
- 16 June 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 112 (3) , 1485-1496
Adverse events of Alzheimer's disease patients treated with memantine-based therapies: A disproportionality analysis of the FAERS database based on the MY FAERS platform
Background: Alzheimer's disease (AD) is commonly treated with memantine alone or in combination with cholinesterase inhibitors (ChEIs) or second-generation antipsychotics (SGAs), but the safety of these combinations remains unclear. Objective: To characterize FDA Adverse Event Reporting System (FAERS)-based signals of disproportionate reporting associated with memantine-based combination therapies in patients with AD. Methods: A disproportionality analysis was conducted using data from FAERS from 2014Q1 to 2025Q2 via the MY FAERS platform. Reporting odds ratios (RORs) with 95% confidence intervals (CI) were calculated to identify safety signals. Sensitivity analyses were conducted using ChEIs or SGAs monotherapy as reference groups to assess the robustness. Results: 2531 patients prescribed memantine were identified, comprising memantine monotherapy (n = 1965), memantine-ChEIs combination (n = 482), and memantine-SGAs combination (n = 84). Compared to memantine monotherapy, the memantine- ChEIs combination showed disproportionate reporting signals for skin (ROR, 3.46; 95% CI, 2.05–5.85), gastrointestinal (ROR, 2.53; 95% CI, 1.92–3.33), musculoskeletal (ROR, 2.13; 95% CI, 1.29–3.50), psychiatric (ROR, 1.60; 95% CI, 1.27–2.00), general (ROR, 1.53; 95% CI, 1.18–1.97), and nervous system disorders (ROR, 1.48; 95% CI, 1.19–1.84). The memantine-SGAs combination was strongly associated with the signals of general (ROR, 3.97; 95% CI, 1.74–9.05), psychiatric (ROR, 2.14; 95% CI, 1.32–3.49), nervous system disorders (ROR, 2.03; 95% CI, 1.20–3.43), and hip fracture (ROR, 15.84; 95% CI, 3.72–67.41). Sensitivity analyses confirmed robustness across subgroups. Conclusions: Memantine-based combination therapies were associated with distinct safety signals of disproportionate reporting compared with monotherapies. These findings should be interpreted as pharmacovigilance signals that warrant cautious interpretation and further validation in well-designed observational or prospective studies.
- 16 June 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 112 (3) , 1485-1496
Adverse events of Alzheimer's disease patients treated with memantine-based therapies: A disproportionality analysis of the FAERS database based on the MY FAERS platform
Background: Alzheimer's disease (AD) is commonly treated with memantine alone or in combination with cholinesterase inhibitors (ChEIs) or second-generation antipsychotics (SGAs), but the safety of these combinations remains unclear. Objective: To characterize FDA Adverse Event Reporting System (FAERS)-based signals of disproportionate reporting associated with memantine-based combination therapies in patients with AD. Methods: A disproportionality analysis was conducted using data from FAERS from 2014Q1 to 2025Q2 via the MY FAERS platform. Reporting odds ratios (RORs) with 95% confidence intervals (CI) were calculated to identify safety signals. Sensitivity analyses were conducted using ChEIs or SGAs monotherapy as reference groups to assess the robustness. Results: 2531 patients prescribed memantine were identified, comprising memantine monotherapy (n = 1965), memantine-ChEIs combination (n = 482), and memantine-SGAs combination (n = 84). Compared to memantine monotherapy, the memantine- ChEIs combination showed disproportionate reporting signals for skin (ROR, 3.46; 95% CI, 2.05–5.85), gastrointestinal (ROR, 2.53; 95% CI, 1.92–3.33), musculoskeletal (ROR, 2.13; 95% CI, 1.29–3.50), psychiatric (ROR, 1.60; 95% CI, 1.27–2.00), general (ROR, 1.53; 95% CI, 1.18–1.97), and nervous system disorders (ROR, 1.48; 95% CI, 1.19–1.84). The memantine-SGAs combination was strongly associated with the signals of general (ROR, 3.97; 95% CI, 1.74–9.05), psychiatric (ROR, 2.14; 95% CI, 1.32–3.49), nervous system disorders (ROR, 2.03; 95% CI, 1.20–3.43), and hip fracture (ROR, 15.84; 95% CI, 3.72–67.41). Sensitivity analyses confirmed robustness across subgroups. Conclusions: Memantine-based combination therapies were associated with distinct safety signals of disproportionate reporting compared with monotherapies. These findings should be interpreted as pharmacovigilance signals that warrant cautious interpretation and further validation in well-designed observational or prospective studies.
- 12 December 2023
- Published by Elsevier in Brain Research
- Vol. 1825, 148711
Asthma aggravates alzheimer's disease by up-regulating NF- κB signaling pathway through LTD4
- 12 December 2023
- Published by Elsevier in Brain Research
- Vol. 1825, 148711
Asthma aggravates alzheimer's disease by up-regulating NF- κB signaling pathway through LTD4
- Open Access
- 21 August 2023
- Published by Wiley in Journal of Chemistry
- Vol. 2023, 1-17
Design, Synthesis, and Neurotrophic Effect of Arg-Glu-Arg-Met-Ser-(3,5)-Dimethyladamantan-1-Amine In Vitro Evaluations as a Potential NMDAR Antagonist
Methyl-D-aspartate receptor (NMDAR) is an ionotropic glutamate receptor and plays an important role in neuronal degradation of Alzheimers disease (AD). According to molecular modeling docking studies, we have designed the compound Arg-Glu-Arg-Met-Ser-(3,5)-dimethyladamantan-1-amine (RERMS-MEM), consisting of an AβPP 5-mer peptide (RERMS) and memantine (MEM). This compound could dock into the active sites of N-methyl-D-aspartate receptor type 2B (NMDAR2B) with a 64.14kcal/mol CDOCKER interaction energy. The stability of RERMS-MEM was evaluated through a 50ns molecular dynamics simulation. The results revealed that the docked ligand-receptor complex was stable. Furthermore, surface plasmon resonance (SPR) revealed that the RERMS-MEM binding affinity to the NMDAR2B fragment exhibited over 15-fold enhancement compared to MEM. The SH-SY5Y cell assays showed that RERMS-MEM or RERMS at concentrations of 0.1, 1, 10, or 50μM could enhance the metabolic rate, and MEM showed no difference compared to the control and indicated cytotoxic effects at 50μM. RERMS-MEM at concentrations of 0.01, 0.1, 1, 10, or 50μM increased the number of viable cells and reduced the release of lactate dehydrogenase (LDH). RERMS at concentrations of 10 or 50μM was similar to RERMS-MEM for increasing viable cells, and MEM showed no difference compared to the control and decreased the number of viable cells at 50μM. RERMS-MEM or RERMS at concentrations of 10 or 50μM could antagonize Aβ25-35-induced cytotoxicity, and MEM at 50μM strengthened the cytotoxicity effects. The results revealed that RERMS-MEM showed a strong NMDAR-blocking activity as a potential NMDAR antagonist, enhancing the neurotrophic effect and cellular growth in SH-SY5Y cells.
- 21 August 2023
- Published by Wiley in Journal of Chemistry
- Vol. 2023, 1-17
Open AccessDesign, Synthesis, and Neurotrophic Effect of Arg-Glu-Arg-Met-Ser-(3,5)-Dimethyladamantan-1-Amine In Vitro Evaluations as a Potential NMDAR Antagonist
Methyl-D-aspartate receptor (NMDAR) is an ionotropic glutamate receptor and plays an important role in neuronal degradation of Alzheimers disease (AD). According to molecular modeling docking studies, we have designed the compound Arg-Glu-Arg-Met-Ser-(3,5)-dimethyladamantan-1-amine (RERMS-MEM), consisting of an AβPP 5-mer peptide (RERMS) and memantine (MEM). This compound could dock into the active sites of N-methyl-D-aspartate receptor type 2B (NMDAR2B) with a 64.14kcal/mol CDOCKER interaction energy. The stability of RERMS-MEM was evaluated through a 50ns molecular dynamics simulation. The results revealed that the docked ligand-receptor complex was stable. Furthermore, surface plasmon resonance (SPR) revealed that the RERMS-MEM binding affinity to the NMDAR2B fragment exhibited over 15-fold enhancement compared to MEM. The SH-SY5Y cell assays showed that RERMS-MEM or RERMS at concentrations of 0.1, 1, 10, or 50μM could enhance the metabolic rate, and MEM showed no difference compared to the control and indicated cytotoxic effects at 50μM. RERMS-MEM at concentrations of 0.01, 0.1, 1, 10, or 50μM increased the number of viable cells and reduced the release of lactate dehydrogenase (LDH). RERMS at concentrations of 10 or 50μM was similar to RERMS-MEM for increasing viable cells, and MEM showed no difference compared to the control and decreased the number of viable cells at 50μM. RERMS-MEM or RERMS at concentrations of 10 or 50μM could antagonize Aβ25-35-induced cytotoxicity, and MEM at 50μM strengthened the cytotoxicity effects. The results revealed that RERMS-MEM showed a strong NMDAR-blocking activity as a potential NMDAR antagonist, enhancing the neurotrophic effect and cellular growth in SH-SY5Y cells.
- Open Access
- 31 May 2022
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 26 (6) , 424-433
Low-Dose NOACs Versus Standard-Dose NOACs or Warfarin on Efficacy and Safety in Asian Patients with NVAF: A Meta-Analysis
Atrial fibrillation,NOACs,warfarin,meta-analysis
- 31 May 2022
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 26 (6) , 424-433
Open AccessLow-Dose NOACs Versus Standard-Dose NOACs or Warfarin on Efficacy and Safety in Asian Patients with NVAF: A Meta-Analysis
Atrial fibrillation,NOACs,warfarin,meta-analysis
- Open Access
- 7 March 2022
- Published by Wiley in Cardiology Research and Practice
- Vol. 2022, 1-10
Real-World Comparisons of Low-Dose NOACs versus Standard-Dose NOACs or Warfarin on Efficacy and Safety in Patients with AF: A Meta-Analysis
Objective. We aimed to further investigate the efficacy and safety of low-dose NOACs by performing a meta-analysis of cohort studies. Background. Meta-analyses of randomized controlled trials (RCTs) have demonstrated that low-dose non-vitamin K antagonist oral anticoagulants (NOACs) showed inferior efficacy compared with standard-dose NOACs, although they are still frequently prescribed for patients with atrial fibrillation (AF) in the clinical practice. Methods. Cochrane Central Register of Controlled Trials (CENTRAL), Embase, and MEDLINE were systematically searched from the inception to September 9, 2021, for cohort studies that compared the efficacy and/or safety of low-dose NOACs in patients with AF. The primary outcomes were ischemic stroke and major bleeding, and the secondary outcomes were mortality, intracranial hemorrhage (ICH), and gastrointestinal hemorrhage (GH). Hazard ratios (HRs) and 95 confidence intervals (CIs) were estimated with the random-effect model. Results. Twenty-five publications involving 487856 patients with AF were included. Compared with standard-dose NOACs, low-dose NOACs had comparable risks of ischemic stroke (HR=1.03, 95 CI 0.96 to 1.11), major bleeding (HR=1.12, 95 CI 0.97 to 1.28), ICH (HR=1.09, 95 CI 0.88 to 1.36), and GH (HR=1.11, 95 CI 0.92 to 1.33), except for a higher risk of mortality (HR=1.41, 95 CI 1.21 to 1.65). Compared with warfarin, low-dose NOACs were associated with lower risks of ischemic stroke (HR=0.72, 95 CI .67 to 0.78), mortality (HR=0.67, 95 CI 0.59 to 0.77), major bleeding (HR=0.64, 95 CI 0.53 to 0.79), ICH (HR=0.57, 95 CI 0.42 to 0.77), and GH (HR=0.78, 95 CI 0.64 to 0.95). Conclusions. Low-dose NOACs were comparable to standard-dose NOACs considering risks of ischemic stroke, major bleeding, ICH, and GH, and they were superior to warfarin. Low-dose NOACs might be prescribed effectively and safely for patients with AF. Considering limitations, further well-designed prospective studies are foreseen.
- 7 March 2022
- Published by Wiley in Cardiology Research and Practice
- Vol. 2022, 1-10
Open AccessReal-World Comparisons of Low-Dose NOACs versus Standard-Dose NOACs or Warfarin on Efficacy and Safety in Patients with AF: A Meta-Analysis
Objective. We aimed to further investigate the efficacy and safety of low-dose NOACs by performing a meta-analysis of cohort studies. Background. Meta-analyses of randomized controlled trials (RCTs) have demonstrated that low-dose non-vitamin K antagonist oral anticoagulants (NOACs) showed inferior efficacy compared with standard-dose NOACs, although they are still frequently prescribed for patients with atrial fibrillation (AF) in the clinical practice. Methods. Cochrane Central Register of Controlled Trials (CENTRAL), Embase, and MEDLINE were systematically searched from the inception to September 9, 2021, for cohort studies that compared the efficacy and/or safety of low-dose NOACs in patients with AF. The primary outcomes were ischemic stroke and major bleeding, and the secondary outcomes were mortality, intracranial hemorrhage (ICH), and gastrointestinal hemorrhage (GH). Hazard ratios (HRs) and 95 confidence intervals (CIs) were estimated with the random-effect model. Results. Twenty-five publications involving 487856 patients with AF were included. Compared with standard-dose NOACs, low-dose NOACs had comparable risks of ischemic stroke (HR=1.03, 95 CI 0.96 to 1.11), major bleeding (HR=1.12, 95 CI 0.97 to 1.28), ICH (HR=1.09, 95 CI 0.88 to 1.36), and GH (HR=1.11, 95 CI 0.92 to 1.33), except for a higher risk of mortality (HR=1.41, 95 CI 1.21 to 1.65). Compared with warfarin, low-dose NOACs were associated with lower risks of ischemic stroke (HR=0.72, 95 CI .67 to 0.78), mortality (HR=0.67, 95 CI 0.59 to 0.77), major bleeding (HR=0.64, 95 CI 0.53 to 0.79), ICH (HR=0.57, 95 CI 0.42 to 0.77), and GH (HR=0.78, 95 CI 0.64 to 0.95). Conclusions. Low-dose NOACs were comparable to standard-dose NOACs considering risks of ischemic stroke, major bleeding, ICH, and GH, and they were superior to warfarin. Low-dose NOACs might be prescribed effectively and safely for patients with AF. Considering limitations, further well-designed prospective studies are foreseen.